Stryker (NYSE:SYK) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Stryker (NYSE:SYK) posted its quarterly earnings results on Tuesday. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14, Zacks reports. Stryker had a return on equity of 23.07% and a net margin of 16.34%. During the same period in the previous year, the firm posted $3.46 EPS. Stryker updated its FY 2025 guidance to 13.450-13.700 EPS.

Stryker Stock Performance

Shares of NYSE SYK opened at $390.98 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker has a 1 year low of $314.05 and a 1 year high of $406.19. The company’s fifty day moving average price is $376.44 and its 200 day moving average price is $361.98. The company has a market capitalization of $149.05 billion, a PE ratio of 41.91, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker’s payout ratio is presently 36.01%.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

SYK has been the subject of several research reports. Robert W. Baird increased their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Canaccord Genuity Group raised their price target on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. increased their price target on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research report on Wednesday. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $413.45.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.